Scopus BioPharma (Scopus BioPharma) ROC (Joel Greenblatt) % : -585,800.00% (As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Scopus BioPharma ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Scopus BioPharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -585,800.00%.

The historical rank and industry rank for Scopus BioPharma's ROC (Joel Greenblatt) % or its related term are showing as below:

SCPS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1047160 Med: -403566.67 Max: -67250
Current: -389333.33

During the past 6 years, Scopus BioPharma's highest ROC (Joel Greenblatt) % was -67250.00%. The lowest was -1047160.00%. And the median was -403566.67%.

SCPS's ROC (Joel Greenblatt) % is ranked worse than
99.52% of 1459 companies
in the Biotechnology industry
Industry Median: -322.46 vs SCPS: -389333.33

Scopus BioPharma's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.

Scopus BioPharma ROC (Joel Greenblatt) % Historical Data

The historical data trend for Scopus BioPharma's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scopus BioPharma ROC (Joel Greenblatt) % Chart

Scopus BioPharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROC (Joel Greenblatt) %

Get a 7-Day Free Trial

-67,250.00

-338,533.33

-1,047,160.00

-468,600.00

Scopus BioPharma Quarterly Data
	Jun18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
ROC (Joel Greenblatt) %	Get a 7-Day Free Trial															-442,666.67	-253,200.00	-293,760.00	-536,000.00	-585,800.00

Competitive Comparison of Scopus BioPharma's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Scopus BioPharma's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scopus BioPharma's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scopus BioPharma's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Scopus BioPharma's ROC (Joel Greenblatt) % falls into.

Scopus BioPharma ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %

EBIT

Average of (Net fixed Assets

Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

	Working Capital		(Q: Mar. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.2)	-	(9.152	+	0	+	0.161)
=	-9.113

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.134)	-	(10.909	+	0	+	0.093)
=	-10.868

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Scopus BioPharma for the quarter that ended in Jun. 2023 can be restated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2023		Q: Jun. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-11.716	/	( ( (0.002 + max(-9.113, 0))	+	(0.002 + max(-10.868, 0)) )	/	2 )
=	-11.716	/	( ( 0.002	+	0.002 )	/	2 )
=	-11.716	/	0.002
=	-585,800.00 %

Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

Scopus BioPharma (OTCPK:SCPS) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.

Scopus BioPharma ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Scopus BioPharma's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.

Scopus BioPharma (Scopus BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scopus BioPharma Inc (OTCPK:SCPS) » Definitions » ROC (Joel Greenblatt) %

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Lexington Avenue, Suite 300, New York, NY, USA, 10170

Website

https://www.scopusbiopharma.com

Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. The company product candidates would utilize synthetically-produced cannabinoids as opposed to plant-derived compounds. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.

Executives

Ira Scott Greenspan	director	888 SEVENTH AVENUE, 9TH FLOOR, NEW YORK NY 10106
Joshua R Lamstein	director, officer: Chairman	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Alan M Horsager	officer: See Remarks	1021 N EVERETT STREET, GLENDALE CA 91207
Robert J Gibson	director, officer: Vice Chairman	71 LANTERN RIDGE RD, NEW CANAAN CT 06840
Lesley Russell	director	41 MOORES RD., FRAZER PA 19355
Iv David Weild	director	22 ORIOLE AVENUE, BRONXVILLE NY 10708
David S. Battleman	director	C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
David A. Buckel	director	SHARPSPRING, 550 SW 2ND AVENUE, GAINESVILLE FL 32601
Raphael Hofstein	director	C/O HADASSAH, P.O. BOX 12000, JERUSALEM L3 91120
Paul Hopper	director	7982 DOUG HILL, SAN DIEGO CA 92127
Ashish P Sanghrajka	director, officer: President	101 WALL STREET, APARTMENT 19B, NEW YORK NY 10005